International Journal of Celiac Disease
ISSN (Print): 2334-3427 ISSN (Online): 2334-3486 Website: http://www.sciepub.com/journal/ijcd Editor-in-chief: Samasca Gabriel
Open Access
Journal Browser
Go
International Journal of Celiac Disease. 2020, 8(1), 39-43
DOI: 10.12691/ijcd-8-1-8
Open AccessArticle

Novel Coronavirus COVID-19 and Its Diagnosis and Treatments

Vishal Sanklecha1,

1Department of Pharmaceutics, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, India

Pub. Date: April 27, 2020

Cite this paper:
Vishal Sanklecha. Novel Coronavirus COVID-19 and Its Diagnosis and Treatments. International Journal of Celiac Disease. 2020; 8(1):39-43. doi: 10.12691/ijcd-8-1-8

Abstract

Recently, at the end of 2019 in Wuhan, China found a novel flu like Corona virus (COVID-related to the severe acute respiratory syndrome (SARS) in 2002 and Middle East respiratory syndrome (MERS) in 2012 and so many cases it confirmed that, it transmitted through human-to-human and spread all over world. There is no proper medicine and vaccine on this novel coronavirus COVID-19. The Economy of so many countries going on declined state due to this novel coronavirus COVID-19. It is challenge to scientists to find out actual medicine and vaccine on this novel coronavirus COVID-19. The present review is an attempt made in the respect of highlighting the some important information regarding detection and treatments on Novel coronavirus COVID-19.

Keywords:
Coronavirus COVID-19 SARS MERS

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Cohen J, Normile D. New SARS‐like virus in China triggers alarm. Science. 2020: 367; 234‐235.
 
[2]  Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients withpneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727‐733.
 
[3]  Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan,China, of novel coronavirus‐infected pneumonia. New Engl J Med. 2020: 1‐9.
 
[4]  Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses. 2019; 11: 41.
 
[5]  Schoeman D, Fielding BC. Coronavirus envelope protein: currentknowledge. Virol J. 2019; 16: 69.
 
[6]  Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015; 386: 995‐1007.
 
[7]  Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, Coronavirus Investigating, and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020.
 
[8]  Zhang N, Wang L, Deng X, et al. Recent advances in the detection ofrespiratory virus infection in humans. J Med Virol. 2020; 92(4): 408‐417.
 
[9]  Chan JFW, Kok KH, Zhu Z, et al. Genomic characterization of the 2019novel human‐pathogenic coronavirus isolated from a patient with atypicalpneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1): 221‐236.
 
[10]  Zhangkai J, Cheng J, Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus, World Journal of Pediatrics.
 
[11]  World Health Organization. Situation reports. Available at: https://www.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. Accessed 26 March 2020.
 
[12]  Zhi‑Min C, Jun‑Fen F, Qiang S, et al.Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus, World Journal of Pediatrics, 2020.
 
[13]  Chaolin H, Yeming W, Xingwang L. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, www.thelancet.com Vol 395 February 15, 2020, 497-506.
 
[14]  Chen W, Peter H, Frederick H, George G. A noval coronavirus out breack of global health concern. The lancet, 2020.
 
[15]  Wenzel RP, Edmond MB. Managing SARS amidst uncertainty. N Engl J Med. 2003; 348: 1947‐1948.
 
[16]  Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon‐beta synergistically inhibit SARS‐associated coronavirus replication in animal and human cell lines. BiochemBiophys Res Commun. 2005; 326: 905‐908.
 
[17]  Tsang K, Zhong NS. SARS: pharmacotherapy. Respirology. 2003; 8(suppl): S25‐S30.
 
[18]  Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS‐CoV. Nat Commun. 2020; 11: 222.
 
[19]  Chu CM. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59: 252‐256.
 
[20]  Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon‐alpha for Middle East respiratory syndrome. Antivir Ther. 2016; 21: 455‐459.
 
[21]  Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS‐5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018; 9(2): e00221‐18.
 
[22]  Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020: NEJMoa2001191.
 
[23]  Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs. 1998; 56: 147‐167.
 
[24]  Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS‐associated coronavirus. Biochem Biophys Res Commun. 2004; 318: 719‐725.
 
[25]  Pei J, Sekellick MJ, Marcus PI, Choi IS, Collisson EW. Chicken interferontype I inhibits infectious bronchitis virus replication and associated respiratory illness. J Interferon Cytokine Res. 2001; 21: 1071‐1077.
 
[26]  Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha‐2b interferon. J Infect Dis. 1986; 154: 443‐447.
 
[27]  Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon‐beta synergistically inhibit SARS‐associated coronavirus replication in animal and human cell lines. BiochemBiophys Res Commun. 2005; 326: 905‐908.
 
[28]  Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J ClinVirol. 2004; 31: 69‐75.
 
[29]  Bussel JB, Szatrowski TP. Uses of intravenous gammaglobulin in immune hematologic disease. Immunol Invest. 1995; 24: 451‐456.
 
[30]  Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology. 2003; 601736‐1737.
 
[31]  Matteucci C, Grelli S, Balestrieri E, et al. Thymosin alpha 1 and HIV‐1: recent advances and future perspectives. Future Microbiol. 2017; 12: 141‐155.
 
[32]  Costantini C, Bellet MM, Pariano M, et al. A reappraisal of thymosin alpha1 in cancer therapy. Front Oncol. 2019; 9: 873.
 
[33]  Pica F, Gaziano R, Casalinuovo IA, et al. Serum thymosin alpha 1 levels in normal and pathological conditions. Expert OpinBiolTher. 2018; 18: 13‐21.
 
[34]  Gao ZC, Zhu JH, Sun Y, et al. Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome. Zhongguo Wei ZhongBing Ji Jiu Yi Xue. 2003; 15: 332‐335.
 
[35]  Kumar V, Jung YS, Liang PH. Anti‐SARS coronavirus agents: a patent review (2008‐present). Expert OpinTher Pat. 2013; 23: 1337‐1348.
 
[36]  Duchateau J, Servais G, Vreyens R, Delespesse G, Bolla K. Modulation of immune response in aged humans through different administration modes of thymopentin. SurvImmunol Res. 1985; 4(suppl 1): 94‐101.
 
[37]  Duchateau J, Delespesse G, Bolla K. Phase variation in the modulation of the human immune response. Immunol Today. 1983; 4: 213‐214.
 
[38]  Ziaei M, Ziaei F, Manzouri B. Systemic cyclosporine and corneal transplantation. Int Ophthalmol. 2016; 36: 139‐146.
 
[39]  Luo C, Luo H, Zheng S, et al. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem Biophys Res Commun. 2004; 321: 557‐565.
 
[40]  Dawar FU, Tu J, Khattak MN, et al. Factor in virus replication and potential target for anti‐viral therapy. Curr Issues Mol Biol. 2017; 21: 1‐20.
 
[41]  Chen L, Gui C, Luo X, et al. Cinanserin is an inhibitor of the 3C‐like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol. 2005; 79: 7095‐7103.
 
[42]  Park JY, Jeong HJ, Kim JH, et al. Diarylheptanoids from Alnus japonica inhibit papain‐like protease of severe acute respiratory syndrome coronavirus. Biol Pharm Bull. 2012; 35: 2036‐2042.
 
[43]  Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016; 5: e 47.
 
[44]  Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS‐CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020; 35: 145‐151.
 
[45]  Hemila H. Vitamin C and SARS coronavirus. J Antimicrob Chemother.2003; 52: 1049‐1050.
 
[46]  Field CJ, Johnson IR, Schley PD. Nutrients and their role in host resistance to infection. J Leukoc Biol. 2002; 71: 16‐32.
 
[47]  Atherton JG, Kratzing CC, Fisher A. The effect of ascorbic acid on infection chick‐embryo ciliated tracheal organ cultures by coronavirus. Arch Virol. 1978; 56: 195‐199.
 
[48]  Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free‐living healthy young adults. Am J Med. 2002; 112: 659‐662.
 
[49]  Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J ClinNutr. 2004; 80: 1678S‐1688S.
 
[50]  Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003; 3: 722‐727.
 
[51]  Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2: 69.
 
[52]  Alves DS, Perez‐Fons L, Estepa A, Micol V. Membrane‐related effects underlying the biological activity of the anthraquinonesemodin and barbaloin. Biochem Pharmacol. 2004; 68: 549‐561.
 
[53]  Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin‐converting enzyme 2 interaction. Antiviral Res. 2007; 74: 92‐101.
 
[54]  Zhang XW, Yap YL. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem. 2004; 12: 2517‐2521.
 
[55]  https://www.fda.gov/vaccines-blood-biologics/investigational- new-drug-ind-or-device-exemption-ide-process- cber/investigational-covid-19-convalescent-plasma-emergency-inds.